Distributor inventory
Insulin glargine 450 IU/3 mL (U-300; 300 units/mL) solution for injection in prefilled pen (Toujeo SoloStar)
Treatment of diabetes mellitus to improve glycaemic control in adults; also used in children/adolescents as per clinician advice depending on approved local labeling. Used as long-acting (basal) insulin in type 1 diabetes (with mealtime insulin) and type 2 diabetes.
Insulin glargine is a long-acting basal insulin analog. After subcutaneous injection it forms microprecipitates that slowly release insulin, providing a steady glucose-lowering effect over ~24 hours or longer by increasing peripheral glucose uptake and reducing hepatic glucose production.
For subcutaneous injection only using the Toujeo pen. Inject once daily at the same time each day into abdomen, thigh, or upper arm; rotate injection sites. Use as directed by a doctor; do not share pen/needles. Do not dilute or mix with other insulins; not for IV use.
Common side effects of TOUJEO 450 IU may include:
Risk of severe hypoglycaemia—monitor blood glucose and adjust dose with changes in diet, exercise, illness, or other medicines. Not for treatment of diabetic ketoacidosis (use rapid-acting insulin/IV insulin). Do not use in insulin pumps or intravenously. Use caution in renal/hepatic impairment and in elderly; dose adjustments may be needed. Rotate injection sites to reduce lipodystrophy. Seek urgent care for severe allergy, breathing difficulty, or persistent low sugars.
